BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBrOct 21 (Reuters) - GSK plc GSK.L & Spero Therapeutics SPRO.O :
GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBR
GSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR COMPLICATED URINARY TRACT INFECTIONS
GSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENT
GSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN & OTHER CARBAPENEM ANTIBIOTICS
GSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4
Source text: [ID:]
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments